公开(公告)号：US20220119531A1

公开(公告)日：2022-04-21

申请号：US17563502

申请日：2021-12-28

Applicant: I-Mab Biopharma US Limited

Inventor： Lei Fang ,  Yongqiang Wang ,  Zhengyi Wang ,  Bingshi Guo ,  Jingwu Zang

IPC: C07K16/28 ,  A61P35/00

Abstract: Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 116, a VH CDR3 of SEQ ID NO: 117, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

公开(公告)号：US11034771B2

公开(公告)日：2021-06-15

申请号：US16963091

申请日：2019-07-25

Applicant: I-Mab Biopharma US Limited

Inventor： Zhengyi Wang ,  Lei Fang ,  Bingshi Guo ,  Jingwu Zang ,  Qiumei Yang

IPC: C07K16/28

Abstract: Provided are bispecific antibodies capable of binding to human CD73 protein and human PD-L1 protein. These bispecific antibodies are effective in treating cancer.

公开(公告)号：US20200332005A1

公开(公告)日：2020-10-22

申请号：US16785953

申请日：2020-02-10

Applicant: I-MAB Biopharma US Limited

Inventor： Zhengyi Wang ,  Lei Fang ,  Bingshi Guo ,  Jingwu Zang

IPC: C07K16/28 ,  A61P35/00 ,  A61K9/00 ,  A61K9/06 ,  A61K35/17 ,  A61K39/395 ,  C07K16/40 ,  G01N33/574

Abstract: Provided are anti-CD73 antibodies or fragments thereof. The antibodies or fragments therefore include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. More generally, antibodies or fragments thereof are described which have specificity to one or more amino acid residues selected from the C-terminal half of a human CD73 protein, such as those in the C-terminal domains. Specific epitope amino acids in these domains include Y345, D399, E400, R401 and R480. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer are also provided.

公开(公告)号：US12195538B2

公开(公告)日：2025-01-14

申请号：US17298741

申请日：2019-02-15

Applicant: ABL BIO INC. ,  I-MAB BIOPHARMA US LIMITED

Inventor： Eunyoung Park ,  Yangsoon Lee ,  Hyejin Chung ,  Eunsil Sung ,  Jiseon Yoo ,  Minji Park ,  Yong-Gyu Son ,  Hyoju Choi ,  Eunjung Kim ,  Jaeho Jung ,  Weon-Kyoo You ,  Sang Hoon Lee ,  Lei Fang ,  Wenqing Jiang

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/46

Abstract: The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.

公开(公告)号：US11613577B2

公开(公告)日：2023-03-28

申请号：US16785953

申请日：2020-02-10

Applicant: I-MAB Biopharma US Limited

Inventor： Zhengyi Wang ,  Lei Fang ,  Bingshi Guo ,  Jingwu Zang

IPC: C07K16/00 ,  C07K16/28 ,  A61P35/00 ,  A61K9/00 ,  A61K9/06 ,  A61K35/17 ,  A61K39/395 ,  C07K16/40 ,  G01N33/574 ,  A61K39/00

Abstract: Provided are anti-CD73 antibodies or fragments thereof. The antibodies or fragments therefore include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. More generally, antibodies or fragments thereof are described which have specificity to one or more amino acid residues selected from the C-terminal half of a human CD73 protein, such as those in the C-terminal domains. Specific epitope amino acids in these domains include Y345, D399, E400, R401 and R480. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer are also provided.

公开(公告)号：US20220348675A1

公开(公告)日：2022-11-03

申请号：US17683869

申请日：2022-03-01

Applicant: I-Mab Biopharma US Limited ,  ABL Bio Inc.

Inventor： Wenqing Jiang ,  Lei Fang ,  Zhengyi Wang ,  Bingshi Guo ,  Eunyoung Park ,  Eunsil Sung ,  Byungje Sung

IPC: C07K16/28 ,  A61P35/00

Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.

公开(公告)号：US20210269522A1

公开(公告)日：2021-09-02

申请号：US17257294

申请日：2019-10-31

Applicant: I-Mab Biopharma US Limited

Inventor： Zhengyi Wang ,  Wei Cao ,  Lei Fang ,  Bingshi Guo

IPC: C07K16/28 ,  A61P35/00 ,  C07K14/535 ,  C12N9/80

Abstract: Provided are pharmaceutical compositions each comprising a glycosylation agent, an antibody that binds to human CD47, and a pharmaceutically acceptable carrier. Also provided are novel CD47 antibodies that bind to human CD47, wherein the antibodies bind to at least one epitope that is at one of the glycosylation sites of the CD47 protein of red blood cells (e. g, at least a glycosylation site near the epitope residues Gln31 and Thr34 in CD47).

公开(公告)号：US11208486B2

公开(公告)日：2021-12-28

申请号：US17277909

申请日：2020-04-26

Applicant: I-Mab Biopharma US Limited

Inventor： Lei Fang ,  Yuanyuan Yang ,  Zhengyi Wang ,  Bingshi Guo ,  Feifei Cui

IPC: C07K16/00 ,  C07K16/28 ,  A61P35/00 ,  A61K39/00

Abstract: Provided are full human anti-PD-L1 antibodies or fragments thereof. In various examples, the antibodies or fragments thereof include a VH CDR1, a VH CDR2, a VH CDR3, a VL CDR1, a VL CDR2, and a VL CDR3 which are selected from sequence groups of SEQ ID NO: 35-42, SEQ ID NO: 43-51, SEQ ID NO: 52-66, SEQ ID NO: 67-79, SEQ ID NO:80-88 and SEQ ID NO: 89-102, respectively, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

公开(公告)号：US20200377611A1

公开(公告)日：2020-12-03

申请号：US16989670

申请日：2020-08-10

Applicant: I-Mab Biopharma US Limited

Inventor： Zhengyi Wang ,  Lei Fang ,  Bingshi Guo ,  Jingwu Zang

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  C07K16/30 ,  G01N33/68

Abstract: The present invention provides novel CD47 antibodies or immunologically active fragments thereof that have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination, as well as pharmaceutical compositions containing such antibodies that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation.

公开(公告)号：US20200071403A1

公开(公告)日：2020-03-05

申请号：US16687387

申请日：2019-11-18

Applicant: I-MAB Biopharma US Limited

Inventor： Lei Fang ,  Zhengyi Wang ,  Bingshi Guo ,  Jingwu Zang ,  Wenqing Jiang ,  Yongqiang Wang

IPC: C07K16/28 ,  A61K35/17 ,  A61P37/04 ,  A61P35/00

Abstract: The present disclosure provides antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease.